```
=> d his

     (FILE 'HOME' ENTERED AT 13:02:29 ON 10 JAN 2003)

     FILE 'CA, MEDLINE, BIOSIS' ENTERED AT 13:02:49 ON 10 JAN 2003
L1       121708 S GELATIN?
L2       116614 S ALKALINE PHOSPHATASE?
L3       547534 S INSULIN?
L4            6 S L1 AND L2 AND L3
L5            5 DUP REM L4 (1 DUPLICATE REMOVED)

=>
```

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1815mxw

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Apr 08  "Ask CAS" for self-help around the clock
 NEWS  3  Apr 09  BEILSTEIN: Reload and Implementation of a New Subject Area
 NEWS  4  Apr 09  ZDB will be removed from STN
 NEWS  5  Apr 19  US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
 NEWS  6  Apr 22  Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
 NEWS  7  Apr 22  BIOSIS Gene Names now available in TOXCENTER
 NEWS  8  Apr 22  Federal Research in Progress (FEDRIP) now available
 NEWS  9  Jun 03  New e-mail delivery for search results now available
 NEWS 10  Jun 10  MEDLINE Reload
 NEWS 11  Jun 10  PCTFULL has been reloaded
 NEWS 12  Jul 02  FOREGE no longer contains STANDARDS file segment
 NEWS 13  Jul 22  USAN to be reloaded July 28, 2002;
                  saved answer sets no longer valid
 NEWS 14  Jul 29  Enhanced polymer searching in REGISTRY
 NEWS 15  Jul 30  NETFIRST to be removed from STN
 NEWS 16  Aug 08  CANCERLIT reload
 NEWS 17  Aug 08  PHARMAMarketLetter(PHARMAML) - new on STN
 NEWS 18  Aug 08  NTIS has been reloaded and enhanced
 NEWS 19  Aug 19  Aquatic Toxicity Information Retrieval (AQUIRE)
                  now available on STN
 NEWS 20  Aug 19  IFIPAT, IFICDB, and IFIUDB have been reloaded
 NEWS 21  Aug 19  The MEDLINE file segment of TOXCENTER has been reloaded
 NEWS 22  Aug 26  Sequence searching in REGISTRY enhanced
 NEWS 23  Sep 03  JAPIO has been reloaded and enhanced
 NEWS 24  Sep 16  Experimental properties added to the REGISTRY file
 NEWS 25  Sep 16  Indexing added to some pre-1967 records in CA/CAPLUS
 NEWS 26  Sep 16  CA Section Thesaurus available in CAPLUS and CA
 NEWS 27  Oct 01  CASREACT Enriched with Reactions from 1907 to 1985
 NEWS 28  Oct 21  EVENTLINE has been reloaded
 NEWS 29  Oct 24  BEILSTEIN adds new search fields
 NEWS 30  Oct 24  Nutraceuticals International (NUTRACEUT) now available on STN
 NEWS 31  Oct 25  MEDLINE SDI run of October 8, 2002
 NEWS 32  Nov 18  DKILIT has been renamed APOLLIT
 NEWS 33  Nov 25  More calculated properties added to REGISTRY
 NEWS 34  Dec 02  TIBKAT will be removed from STN
 NEWS 35  Dec 04  CSA files on STN
 NEWS 36  Dec 17  PCTFULL now covers WP/PCT Applications from 1978 to date
 NEWS 37  Dec 17  TOXCENTER enhanced with additional content
 NEWS 38  Dec 17  Adis Clinical Trials Insight now available on STN
 NEWS 39  Dec 30  ISMEC no longer available

 NEWS EXPRESS  January 6 CURRENT WINDOWS VERSION IS V6.01a,
               CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
```

```
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:02:29 ON 10 JAN 2003

=> sis, medline
SIS, IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> file ca, medline, biosis
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'CA' ENTERED AT 13:02:49 ON 10 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 13:02:49 ON 10 JAN 2003

FILE 'BIOSIS' ENTERED AT 13:02:49 ON 10 JAN 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

=> s gelatin?
L1      121708 GELATIN?

=> s alkaline phosphatase?
L2      116614 ALKALINE PHOSPHATASE?

=> s insulin?
L3      547534 INSULIN?

=> s l1 and l2 and l3
L4            6 L1 AND L2 AND L3

=> dup rem l4
PROCESSING COMPLETED FOR L4
L5            5 DUP REM L4 (1 DUPLICATE REMOVED)

=> d 1-5 ab,bib

L5   ANSWER 1 OF 5  CA  COPYRIGHT 2003 ACS
AB   A porous .beta.-tricalcium phosphate material for bone implantation is
     provided.  The multiple pores in the porous TCP body are sep. discrete
     voids and are not interconnected.  The pore size diam. is in the range of
     20-500 .mu.m, preferably 50-125 .mu.m.  The porous .beta.-TCP material
     provides a carrier matrix for bioactive agents and can form a moldable
     putty compn. upon the addn. of a binder.  Preferably, the bioactive agent
     is encapsulated in a biodegradable agent.  The invention provides a kit
     and an implant device comprising the porous .beta.-TCP, and a bioactive
```

agent and a binder. The invention also provides an implementable prosthetic device comprising a prosthetic implant having a surface region, a porous .beta.-TCP material disposed on the surface region optionally comprising at least a bioactive agent or a binder. Methods of producing the porous .beta.-TCP material and including bone formation are also provided.

AN 137:237785 CA

TI Porous beta-tricalcium phosphate granules for bone implantation, and methods for producing same

IN Dalal, Paresh S.; Dimaano, Godofredo R.; Toth, Carol Ann; Kulkarni, Shailesh C.

PA Stryker Corporation, USA

SO PCT Int. Appl., 151 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002070029	A2	20020912	WO 2002-US5827	20020226

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-798518 A 20010302
US 2001-960789 A 20010921

L5 ANSWER 2 OF 5 CA COPYRIGHT 2003 ACS

AB It has been found that placental alk. phosphatase interacts synergistically with growth factors and corresponding serum factors to stimulate the proliferation of adult fibroblast cells. Furthermore, this stimulation of fibroblast proliferation does not result in a corresponding stimulation of collagen synthesis. Thus, wound healing compns. can be formulated that improve wound healing without increasing scar formation. Compns. for wound healing can include placental alk. phosphatase and a gel-forming material. In some embodiments, compns. include placental alk. phosphatase and serum/growth factors. In addn. to wound healing applications, compns. with placental alk. phosphatase can also be used in cell culturing of adult fibroblast cells. Placental alk. phosphatase at a concn. of 2 unit/mL increased the no. cultured fibroblasts and the amt. of DNA synthesis.

AN 137:222124 CA

TI Use of placental **alkaline phosphatase** for stimulating wound healing and fibroblast proliferation

IN Kiss, Zoltan

PA USA

SO U.S. Pat. Appl. Publ., 24 pp.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002127216	A1	20020912	US 2001-873654	20010604
WO 2002072136	A1	20020919	WO 2002-US7350	20020311

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-274852P P 20010309
US 2001-873654 A1 20010604

L5 ANSWER 3 OF 5 CA COPYRIGHT 2003 ACS

AB A microsphere compn. for sustained release of therapeutic or diagnostic agents comprises (1) a carrier protein, (2) a water-sol. polymer, (3) a polyanionic polysaccharide as a first complexing agent, and (4) a divalent metal cation (Ca and Mg) as a second complexing agent. The microspheres have a smooth surface that includes a plurality of channel openings that are < 1000 .ANG. in diam. Various drugs were encapsulated into microspheres. For example, microspheres contg. leuprolide acetate were prepd. using human serum albumin (HSA), dextran sulfate, polyethylene glycol, and polyvinylpyrrolidone. The microspheres were composed of approx. 10% leuprolide acetate, 50% human serum albumin, 20% dextran sulfate and 20% polyethylene glycol/polyvinylpyrrolidone. Similar particles were prepd. which also included zinc sulfate or caprylic acid, both of which retarded the release of protein and peptide from the microspheres. Also, rifampicin-contg. HSA microspheres were prepd. with HSA incorporation of 74% and rifampicin incorporation into the particles of > 6.8%. The av. size of the particles was detd. to be 68 nm in diam.

AN 134:331616 CA

TI Sustained release microspheres based on a carrier protein, a water soluble polymer and complexing agents

IN Scott, Terrence L.; Brown, Larry R.; Riske, Frank J.; Blizzard, Charles D.; Rashba-Step, Julia

PA Epic Therapeutics, Inc., USA

SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001028524	A1	20010426	WO 2000-US28200	20001012

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6458387	B1	20021001	US 1999-420361	19991018
EP 1223917	A1	20020724	EP 2000-973477	20001012

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

PRAI US 1999-420361 A 19991018
WO 2000-US28200 W 20001012

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 5 CA COPYRIGHT 2003 ACS

AB Methods for forming sustained release microspheres and the products produced thereby are provided. The microspheres have a smooth surface that includes a plurality of channel openings that are less than 1000 .ANG. in diam. The microspheres comprise (1) a macromol. such as a

protein and nucleic acid, (2) .gtoreq. 1 water-sol. polymers such as starch, PEG, and PVP, and (3) a complexing agent, which is capable of interacting with a therapeutic agent to facilitate loading, retaining, and/or otherwise delaying the release of the therapeutic agent from the microspheres. Carbonyldiimidazole was added to a soln. of rifampicin in DMF. To the mixt. was added a mixt. of human serum albumin and deionized water. A polymer soln. contg. PVP and PEG in NaOAc soln. was added to the mixt. and the resulting mixt. was incubated and cooled. Particles were isolated and resuspended in water. The av. size of the particles were detd. to be 68 nm in diam.

AN 134:46804 CA

TI Sustained release microspheres comprising macromolecules and water-soluble polymers

IN Scott, Terence L.; Brown, Larry R.; Riske, Frank J.; Blizzard, Charles D.; Rashba-Step, Julia

PA Epic Therapeutics, Inc., USA

SO Eur. Pat. Appl., 38 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1060741	A1	20001220	EP 1999-304616	19990614

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRAI EP 1999-304616 19990614

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 5 MEDLINE DUPLICATE 1

AB Abnormalities in extracellular matrix degradation may play a pathogenetic role in diabetic nephropathy. Cultured renal mesangial cells are known to synthesize increased amounts of matrix proteins when incubated in high glucose media (e.g., 30 mmol/l). However, the effect of glucose loading on degradative enzymes is unknown. Primary cultures of rat mesangial cells were grown until confluent in the presence of fetal calf serum (FCS) and **insulin** (0.67 U/ml). Cells were then cultured for 7 days in plastic wells in either 10 or 30 mmol/l glucose media containing neither FCS nor **insulin**. Collagenase activity in media were determined by zymography and quantitative spectrofluorometry. Cathepsin B and D activities in cell extracts were measured by spectrofluorometry (using the fluorescent substrate Z-Arg-Arg-7-amido-4-methylcoumarin) and 125I-labeled hemoglobin digestion, respectively. **Gelatin**-degrading activity of live mesangial cells was also determined. mRNA levels for collagenase IV, cathepsin B, and cathepsin D were determined by Northern analysis. A major band of collagenase activity with a molecular size of 72 kDa was observed in all mesangial cell media. Exposure of cells to high glucose media resulted in significant reductions in collagenase and cathepsin B activities as well as impairment in **gelatin**-degrading activity. Collagenase IV and cathepsin B and D mRNA levels were also decreased by glucose loading. To exclude the possibility that glucose loading was injurious to cells, 3H-leucine uptake (as a measure of protein synthesis) and membrane **alkaline phosphatase** activity (as a biochemical marker of viability) were not affected by the high glucose condition.(ABSTRACT TRUNCATED AT 250 WORDS)

AN 95347541 MEDLINE

DN 95347541 PubMed ID: 7621999

TI Decreased degradative enzymes in mesangial cells cultured in high glucose media.

AU Leehey D J; Song R H; Alavi N; Singh A K

CS Veterans Affairs Hospital, Hines, IL 60141, USA.

NC DK-35804 (NIDDK)

SO DIABETES, (1995 Aug) 44 (8) 929-35.

Journal code: 0372763. ISSN: 0012-1797.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 199508
ED Entered STN: 19950911
Last Updated on STN: 20000303
Entered Medline: 19950831